Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

Targeting the innate immune system has attracted attention with the development of anti‐ CD47 antibodies. Anti‐CD47 antibodies block the inhibition of the phagocytic activity of macro-phages caused by the up‐regulation of CD47 on tumor cells. In this study, public genomic data was used to identify genes highly expressed in breast tumors with elevated CD47 expression and ana-lyzed the association between the presence of tumor immune infiltrates and the expression of the selected genes. We found that 142 genes positively correlated with CD47, of which 83 predicted favorable and 32 detrimental relapse‐free survival (RFS). From those associated with favorable RFS, we selected the genes with immunologic biological functions and defined a CD47‐immune signature composed of PTPRC, HLA‐E, TGFBR2, PTGER4, ETS1, and OPTN. In the basal‐like and HER2+ breast cancer subtypes, the expression of the CD47‐immune signature predicted favorable outcome, correlated with the presence of tumor immune infiltrates, and with gene expression signatures of T cell activation. Moreover, CD47 up‐regulated genes associated with favorable survival correlated with pro‐tumoral macrophages. In summary, we described a CD47‐immune gene signature composed of 6 genes associated with favorable prognosis, T cell activation, and pro‐tumoral macro-phages in breast cancer tumors expressing high levels of CD47. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.